PBMCs extracted from patients with AML and treated with midostaurin also displayed a slight decrease in FOXP3 mRNA expression compared to the untreated PBMCs; however, the difference was not statistically significant (N = 6, 4–55% decrease, P = 0.30, Fig. 4C). This evidence concerns the gene FOXP3 and acute myeloid leukemia.